(BCX) Bioceltix S.A. - Performance 66.7% in 12m
Compare BCX with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
70.74%
#5 in Group
Rel. Strength
93.60%
#513 in Universe
Total Return 12m
66.67%
#15 in Group
Total Return 5y
231.43%
#10 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -3.39%
(?) Percentile in Group
12m Total Return: BCX (66.7%) vs XBI (-12.1%)
5y Drawdown (Underwater) Chart
Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| ABBV NYSE AbbVie |
-19.2% | 9.47% | 151% | 75.1 | 14.6 | 0.38 | -49.6% | -19% |
| UTHR NASDAQ United Therapeutics |
-11.7% | 23% | 168% | 11.8 | 10.6 | 1.43 | 83.8% | 78.5% |
| HLN NYSE Haleon |
-1.45% | 26.1% | 39.7% | 24.7 | 20.3 | 1.8 | 27.1% | - |
| AMGN NASDAQ Amgen |
-10.9% | 9.64% | 39.3% | 38.4 | 14.1 | 0.99 | -18.8% | -20% |
| LONN SW Lonza |
-3.29% | 3.72% | 31.6% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
| BIM PA Biomerieux |
2.96% | 17.6% | 11.9% | 31.5 | 25.4 | 1.47 | -58.7% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
-10.2% | -24.7% | -1.51% | 29.1 | 20.7 | 0.27 | 61.5% | 31.6% |
| KMDA NASDAQ Kamada |
-6.62% | 33.3% | -5.06% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
Performance Comparison: BCX vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for BCX
| Total Return (including Dividends) | BCX | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 16.12% | -14.90% | -7.04% |
| 3 Months | 37.77% | -14.51% | -10.88% |
| 12 Months | 66.67% | -12.11% | 5.72% |
| 5 Years | 231.43% | -20.56% | 100.77% |
| Trend Score (consistency of price movement) | BCX | XBI | S&P 500 |
| 1 Month | 42.0% | -85.2% | -76.1% |
| 3 Months | 85.7% | -87.6% | -86.4% |
| 12 Months | 91.2% | -24% | 67.8% |
| 5 Years | 82.7% | -52.8% | 84.3% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
| 1 Month | #9 | 36.5% | 24.9% |
| 3 Month | #8 | 61.2% | 54.6% |
| 12 Month | #14 | 89.6% | 57.6% |
| 5 Years | #5 | 475% | 181% |
FAQs
Does BCX Bioceltix S.A. outperforms the market?
Yes,
over the last 12 months BCX made 66.67%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.11%.
Over the last 3 months BCX made 37.77%, while XBI made -14.51%.
Over the last 3 months BCX made 37.77%, while XBI made -14.51%.
Performance Comparison BCX vs Indeces and Sectors
BCX vs. Indices BCX is Over or Underperforming
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 19.7% | 23.2% | 70.0% | 61.0% |
| US NASDAQ 100 | QQQ | 20.2% | 24.0% | 70.1% | 63.0% |
| US Dow Jones Industrial 30 | DIA | 17.8% | 21.3% | 68.1% | 60.0% |
| German DAX 40 | DAX | 7.23% | 24.2% | 51.5% | 47.4% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 12.7% | 23.9% | 65.2% | 58.7% |
| Hongkong Hang Seng | HSI | 12.1% | 27.3% | 68.7% | 50.5% |
| India NIFTY 50 | INDA | 15.7% | 12.7% | 70.6% | 66.0% |
| Brasil Bovespa | EWZ | 15.2% | 22.4% | 69.7% | 77.6% |
BCX vs. Sectors BCX is Over or Underperforming
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 19.9% | 23.7% | 61.8% | 53.4% |
| Consumer Discretionary | XLY | 21.3% | 22.3% | 67.8% | 59.3% |
| Consumer Staples | XLP | 14.5% | 16.2% | 62.4% | 54.2% |
| Energy | XLE | 18.8% | 28.0% | 71.1% | 79.5% |
| Financial | XLF | 17.0% | 21.0% | 62.1% | 47.3% |
| Health Care | XLV | 17.3% | 22.9% | 71.2% | 66.8% |
| Industrial | XLI | 17.2% | 22.1% | 70.7% | 62.8% |
| Materials | XLB | 16.2% | 23.6% | 77.5% | 74.6% |
| Real Estate | XLRE | 14.0% | 21.1% | 70.3% | 52.3% |
| Technology | XLK | 20.4% | 26.0% | 76.1% | 69.9% |
| Utilities | XLU | 14.2% | 18.2% | 65.8% | 40.3% |
| Aerospace & Defense | XAR | 15.1% | 16.7% | 60.6% | 43.5% |
| Biotech | XBI | 15.2% | 31.0% | 85.9% | 78.8% |
| Homebuilder | XHB | 20.3% | 25.3% | 89.5% | 78.4% |
| Retail | XRT | 20.0% | 21.9% | 77.3% | 73.7% |